JP2012505891A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505891A5
JP2012505891A5 JP2011532175A JP2011532175A JP2012505891A5 JP 2012505891 A5 JP2012505891 A5 JP 2012505891A5 JP 2011532175 A JP2011532175 A JP 2011532175A JP 2011532175 A JP2011532175 A JP 2011532175A JP 2012505891 A5 JP2012505891 A5 JP 2012505891A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
halogen
pyridinyl
alkoxycarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011532175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505891A (ja
JP5529876B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/060436 external-priority patent/WO2010045188A1/en
Publication of JP2012505891A publication Critical patent/JP2012505891A/ja
Publication of JP2012505891A5 publication Critical patent/JP2012505891A5/ja
Application granted granted Critical
Publication of JP5529876B2 publication Critical patent/JP5529876B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011532175A 2008-10-17 2009-10-13 Mmp−13阻害剤として有用なヘテロアリール置換インドール化合物 Expired - Fee Related JP5529876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10620708P 2008-10-17 2008-10-17
US61/106,207 2008-10-17
PCT/US2009/060436 WO2010045188A1 (en) 2008-10-17 2009-10-13 Heteroaryl substituted indole compounds useful as mmp-13 inhibitors

Publications (3)

Publication Number Publication Date
JP2012505891A JP2012505891A (ja) 2012-03-08
JP2012505891A5 true JP2012505891A5 (enExample) 2012-11-29
JP5529876B2 JP5529876B2 (ja) 2014-06-25

Family

ID=41508906

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532175A Expired - Fee Related JP5529876B2 (ja) 2008-10-17 2009-10-13 Mmp−13阻害剤として有用なヘテロアリール置換インドール化合物

Country Status (5)

Country Link
US (1) US8785489B2 (enExample)
EP (1) EP2340243B1 (enExample)
JP (1) JP5529876B2 (enExample)
CA (1) CA2738929A1 (enExample)
WO (1) WO2010045188A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2739488A1 (en) 2008-10-15 2010-04-22 Boehringer Ingelheim International Gmbh Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
US8637550B2 (en) 2008-11-17 2014-01-28 Boehringer Ingelheim International Gmbh Heteroaryl diamide compounds useful as MMP-13 inhibitors
BR112012006630A2 (pt) * 2009-09-24 2016-05-03 Hoffmann La Roche derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
SI2750677T1 (sl) * 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
US10266490B2 (en) * 2012-03-16 2019-04-23 Georgetown University Radioprotector compounds
JP6618901B2 (ja) 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
US10730866B2 (en) * 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
WO2016026078A1 (en) * 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
MX2018006856A (es) 2015-12-07 2018-08-01 Plexxikon Inc Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos.
WO2017165139A1 (en) 2016-03-25 2017-09-28 St. Jude Children's Research Hospital 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane x receptor
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX391344B (es) 2016-07-30 2025-03-21 Bristol Myers Squibb Co Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
KR102519535B1 (ko) 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 피리딜 치환된 인돌 화합물
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
ES2921020T3 (es) 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
BR112020011668A2 (pt) 2017-12-15 2020-11-17 Bristol-Myers Squibb Company compostos de éter de indol substituído
FI3728252T3 (fi) 2017-12-18 2023-10-18 Bristol Myers Squibb Co 4-atsaindoliyhdisteitä
JP7313354B2 (ja) 2017-12-19 2023-07-24 ブリストル-マイヤーズ スクイブ カンパニー Tlr阻害剤として有用なアミド置換されたインドール化合物
BR112020012084A2 (pt) 2017-12-19 2020-11-24 Bristol-Myers Squibb Company compostos de indol substituído úteis como inibidores de tlr
WO2019126082A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company 6-azaindole compounds
US11299501B2 (en) 2017-12-20 2022-04-12 Bristol-Myers Squibb Company Diazaindole compounds
BR112020011984A2 (pt) 2017-12-20 2020-11-17 Bristol-Myers Squibb Company compostos de amino indol úteis como inibidores de tlr
CA3085942A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3628669A1 (en) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
CN112955450A (zh) 2018-10-24 2021-06-11 百时美施贵宝公司 经取代的吲哚和吲唑化合物
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
EP3965888B1 (en) 2019-05-09 2024-08-21 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
JP7652772B2 (ja) * 2019-11-01 2025-03-27 ブリストル-マイヤーズ スクイブ カンパニー 置換ピラゾール化合物
AR123281A1 (es) 2020-08-19 2022-11-16 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como inhibidores de tlr9
AR123286A1 (es) 2020-08-19 2022-11-16 Bristol Myers Squibb Co Compuestos de benzimidazol sustituidos útiles como inhibidores de tlr9
AU2021328577A1 (en) 2020-08-19 2023-03-23 Bristol-Myers Squibb Company 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis
CN116947821B (zh) * 2022-04-20 2025-10-17 成都肯迪特生物医药科技有限公司 一种化合物及其在制备jak激酶抑制剂中的用途
US20260092058A1 (en) 2024-09-30 2026-04-02 St. Jude Children's Research Hospital, Inc. Small Molecule Degraders and Fluorescent Probes of PXR

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151380A (ja) * 1994-11-29 1996-06-11 Kyorin Pharmaceut Co Ltd ビス(トリフルオロメチルピロロインドールカルボン酸エステル)誘導体及びその製造方法
WO2000033836A1 (en) 1998-12-04 2000-06-15 Ontogen Corporation 5-membered heterocycles for the treatment of human diseases involving modulators of selectins
GB0018758D0 (en) 2000-07-31 2000-09-20 Smithkline Beecham Plc Novel use and compunds
BR0112856A (pt) 2000-07-31 2003-07-01 Smithkline Beecham Plc Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos
AU2001277621A1 (en) 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
AU2002323406A1 (en) * 2001-08-30 2003-03-18 Merck And Co., Inc. Tyrosine kinase inhibitors
EP1501514B1 (en) * 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
DE10229070A1 (de) 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
NZ543482A (en) 2003-05-21 2009-02-28 Prosidion Ltd Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
CA2535665A1 (en) 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
KR20070047763A (ko) 2004-07-20 2007-05-07 시에나 바이오테크 에스.피.에이. 알파7 니코틴성 아세틸콜린 수용체의 조절제 및 그의치료적 용도
MX2007006790A (es) 2004-12-07 2007-08-15 Toyama Chemical Co Ltd Novedosos derivado de acido antranilico o sal del mismo.
EP1838690A2 (en) 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
ES2395952T3 (es) * 2005-03-16 2013-02-18 Toyama Chemical Co., Ltd. Nuevo derivado del ácido antranílico o una sal del mismo
US20060235037A1 (en) * 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
ES2336142T3 (es) 2005-08-19 2010-04-08 Aventis Pharmaceuticals Inc. Combinacion de un agente hipnotico y un compuesto sustituido, con bis arilo y heteroarilo y aplicacion terapeutica del mismo.
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
CA2739488A1 (en) 2008-10-15 2010-04-22 Boehringer Ingelheim International Gmbh Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
US8637550B2 (en) 2008-11-17 2014-01-28 Boehringer Ingelheim International Gmbh Heteroaryl diamide compounds useful as MMP-13 inhibitors

Similar Documents

Publication Publication Date Title
JP2012505891A5 (enExample)
AU2014233414B2 (en) N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
CN110582489A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP2013518110A5 (enExample)
JP2013505969A5 (enExample)
JP2009530283A5 (enExample)
JP2010510231A5 (enExample)
JP2013544854A5 (enExample)
JP2012507566A5 (enExample)
JP2006515858A5 (enExample)
CA2451981A1 (en) 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
JP2008535903A5 (enExample)
JP2012505234A5 (enExample)
JP2016190843A5 (enExample)
JP2007524696A5 (enExample)
JP2016196492A5 (enExample)
JP2013540712A5 (enExample)
JP2016506960A5 (enExample)
JP2011513305A5 (enExample)
JP2015051994A5 (enExample)
BRPI0807581A2 (pt) Moduladores de propriedades farmacocinéticas de produtos terapêuticos
RU2008140943A (ru) Аналоги тиазолидиндиона
JP2017214387A5 (enExample)
JP2017508795A5 (enExample)
RU2015147447A (ru) Производные доластатина 10 и ауристатинов